PURPOSE: The nonrandom translocation t(1;19) has been associated with poor outcome in pediatric B-lineage acute lymphoblastic leukemia (ALL). Because most patients treated by contemporary therapies now achieve improved outcomes, we have reassessed the prognostic significance of t(1;19). PATIENTS AND METHODS: Cytogenetic data were accepted for 1,322 children (<21 years old) with newly diagnosed ALL enrolled between 1988 and 1994 on risk-adjusted studies of the Children's Cancer Group (CCG). Forty-seven patients (3.6%) were t(1;19) positive (+); 1,275 (96.4%) were t(1;19) negative (-). Clinical characteristics and treatment outcome were compared using standard methods. RESULTS: Translocation (1;19)+ patients were more likely than t(1;19)- patients to be 10 years of age or greater (P < .001) or CD10+ CD19+ CD34- (P < .0001), or nonwhite (P = .02). Patients with a balanced t(1;19) were less likely to be hyperdiploid than patients with an unbalanced der(19)t(1;19). Event-free survival (EFS) was similar for the overall group of t(1;19)+ and t(1;19)- patients, with 4-year estimates of 69.5% (SD, 6.8%) and 74.8% (SD, 1.3%; P = .48), respectively. However, patients with unbalanced der(19)t(1;19) had significantly better outcomes than patients with balanced t(1;19): 4-year EFS were 80.6% (SD, 7.1%) and 41.7% (SD, 13.5%), respectively (P = .003). These differences were maintained within the individual studies analyses and after exclusion of t(1;19)+ patients whose cells were hyperdiploid with more than 50 chromosomes. CONCLUSION: The overall group of t(1;19)+ patients, as well as the subgroup with an unbalanced der(19)+ (1;19) had outcomes similar to that of t(1;19)- patients, whereas patients with balanced t(1;19) had poorer outcomes. Thus, although the overall prognostic significance of t(1;19) has been obviated by contemporary risk-adjusted protocols, the balanced t(1;19) translocation remains an adverse prognostic factor.
PURPOSE: The nonrandom translocation t(1;19) has been associated with poor outcome in pediatric B-lineage acute lymphoblastic leukemia (ALL). Because most patients treated by contemporary therapies now achieve improved outcomes, we have reassessed the prognostic significance of t(1;19). PATIENTS AND METHODS: Cytogenetic data were accepted for 1,322 children (<21 years old) with newly diagnosed ALL enrolled between 1988 and 1994 on risk-adjusted studies of the Children's Cancer Group (CCG). Forty-seven patients (3.6%) were t(1;19) positive (+); 1,275 (96.4%) were t(1;19) negative (-). Clinical characteristics and treatment outcome were compared using standard methods. RESULTS: Translocation (1;19)+ patients were more likely than t(1;19)- patients to be 10 years of age or greater (P < .001) or CD10+ CD19+ CD34- (P < .0001), or nonwhite (P = .02). Patients with a balanced t(1;19) were less likely to be hyperdiploid than patients with an unbalanced der(19)t(1;19). Event-free survival (EFS) was similar for the overall group of t(1;19)+ and t(1;19)- patients, with 4-year estimates of 69.5% (SD, 6.8%) and 74.8% (SD, 1.3%; P = .48), respectively. However, patients with unbalanced der(19)t(1;19) had significantly better outcomes than patients with balanced t(1;19): 4-year EFS were 80.6% (SD, 7.1%) and 41.7% (SD, 13.5%), respectively (P = .003). These differences were maintained within the individual studies analyses and after exclusion of t(1;19)+ patients whose cells were hyperdiploid with more than 50 chromosomes. CONCLUSION: The overall group of t(1;19)+ patients, as well as the subgroup with an unbalanced der(19)+ (1;19) had outcomes similar to that of t(1;19)- patients, whereas patients with balanced t(1;19) had poorer outcomes. Thus, although the overall prognostic significance of t(1;19) has been obviated by contemporary risk-adjusted protocols, the balanced t(1;19) translocation remains an adverse prognostic factor.
Authors: Pavan Reddy; Ramesh Shankar; Teena Koshy; Venkatraman Radhakrishnan; Prasanth Ganesan; P K Jayachandran; Manikandan Dhanushkodi; Nikita Mehra; S Krupashankar; P Manasa; R P Nagare; R Swaminathan; Krishnarathinam Kannan; T G Sagar; T S Ganesan Journal: Indian J Hematol Blood Transfus Date: 2019-04-17 Impact factor: 0.900
Authors: Anna Andersson; Tor Olofsson; David Lindgren; Björn Nilsson; Cecilia Ritz; Patrik Edén; Carin Lassen; Johan Råde; Magnus Fontes; Helena Mörse; Jesper Heldrup; Mikael Behrendtz; Felix Mitelman; Mattias Höglund; Bertil Johansson; Thoas Fioretos Journal: Proc Natl Acad Sci U S A Date: 2005-12-14 Impact factor: 11.205
Authors: Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta Journal: Blood Date: 2006-09-26 Impact factor: 22.113
Authors: S Jeha; D Pei; S C Raimondi; M Onciu; D Campana; C Cheng; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Howard; J R Downing; W E Evans; M V Relling; C-H Pui Journal: Leukemia Date: 2009-03-12 Impact factor: 11.528
Authors: Seong Lin Khaw; Santi Suryani; Kathryn Evans; Jennifer Richmond; Alissa Robbins; Raushan T Kurmasheva; Catherine A Billups; Stephen W Erickson; Yuelong Guo; Peter J Houghton; Malcolm A Smith; Hernan Carol; Andrew W Roberts; David C S Huang; Richard B Lock Journal: Blood Date: 2016-06-24 Impact factor: 22.113
Authors: Kajsa Paulsson; Erik Forestier; Mette K Andersen; Kirsi Autio; Gisela Barbany; Georg Borgström; Lucia Cavelier; Irina Golovleva; Sverre Heim; Kristiina Heinonen; Randi Hovland; Johann H Johannsson; Eigil Kjeldsen; Ann Nordgren; Lars Palmqvist; Bertil Johansson Journal: Haematologica Date: 2013-05-03 Impact factor: 9.941